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Summary: After the introduction (1, 2) and methodical evaluation (3, 4) of a new method for the quantitative
measurement of the bone isoenzyme of alkaline phosphatase (test-combination bone alkaline phosphatase,
Boehringer Mannheim), we started a retrospective clinical study for the follow-up investigations of breast
cancer patients. Our aim was to establish the significance of the routinely used tumour markers, CEA and
CA 15-3, in combination with bone alkaline phosphatase for the early detection of metastatic spread to the
bone. We investigated 492 sera from 92 patients suffering from breast carcinoma, and we compared each date
of investigation with the results of the clinical examination and with the results of medical imaging, if that
had been performed. From a previous study involving skeleton scintigraphy (5) we knew that single exami-
nations do not allow a differential diagnosis between benign and malignant disorders of the bone, so we
based our calculations on differences between sequential investigations. We found that in follow-up investi-
gations of patients with breast carcinoma the combined determination of CEA, CA 15-3 and bone alkaline
phosphatase may be indicative for the localisation of metastatic disease. The determination of the bone
alkaline phosphatase is easy to handle with a short assay time and good reproducibility; it can therefore be
recommended.
Introduction ,. ,. ~ ^ ,. -earlier diagnosis of recurrent disease, they are not
Breast cancer is still the most frequent malignant able to discriminate between the localization of the
disease in women, with growing incidence and mor- metastatic spread. Knowing the low specificity and
tality rates in Western countries. In the follow-up of sensitivity of skeleton scintigraphy for the early de-
these tumour patients the early detection of relapse tection of bone metastases and the high risk of the
or metastases is of great importance for successfull development of bone involvement in patients suffering
treatment and therefore influences prognosis. The de- from breast carcinoma, it would be of great interest
termination of tumour markers in serum, like CEA to determine whether the joint assay of bone alkaline
and CA 15-3, is useless for screening or primary di- phosphatase1) and tumour markers would provide an
agnosis of breast carcinoma, but has been found by aid to the localization of the metastatic spread. For
many investigators to be helpful for monitoring the this purpose we determined CA 15-3, CEA, total
course of disease and development of relapse. Al- alkaline phosphatase and bone alkaline phosphatase
though blood markers have an adjunctive role for the in the sera of breast cancer patients and compared
our results with the clinical course, skeleton scinti-
1) Enzyme: alkaline phosphatase, EC 3.1.3.1. graphy and X-ray diagnostics.
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Patients
The present retrospective study was done with frozen sera
stored at — 70 °C in our serum bank. We investigated sera from
92 patients with breast carcinoma. At least three blood samples
and the results of corresponding clinical investigations had to
be available for inclusion of a patient in the study.
























The intervals between two consecutive investigations varied
between 6 days (minimum) and 1085 days (maximum). The
mean interval was 207 days, the median 160 days.
Of the 400 investigations with existing preceding values we
decided not to take into account the last date of investigation
(no confirmed results), in order to guarantee reliable clinical
data. In the same way all investigations with a vague clinical
background or any kind of uncertain and later unconfirmed
results did not enter the subsequent calculations. Therefore the
number of investigations finally entering the evaluation was
significantly lower than mentioned above under "number of
investigations", and the grouping of patients and pairs of in-
vestigations was as follows:
1) first investigation revealed no bone metastases
a) no suspicion of bone metastases during the whole follow-
up (n = 89)
b) first investigation revealed no bone metastases, but bone
metastases developed at some time during the follow-up.
In this case the first investigation included in the study
was the last one without bone metastases (n = 30)
2) first investigation with bone metastases
a) regressive follow-up (n = 10)
b) stable follow-up (n = 8)
c) progressive follow-up (n = 37)
Each patient was likely to be included more than once in the
subsequent calculations. With the exception of group la), all
patients were likely to change their group during the investi-
gation (patients with regressive disease in the beginning devel-
oped progressive disease during the evaluation and vice versa).
Bone alkaline phosphatase
Bone alkaline phosphatase was determined according to the
method of Rosalki & Foo (1) by precipitation with wheat germ
lectin (test combination BAP, Boehringer Mannheim; inter-
assay CV: 10%).
CA 75-3
The cancer antigen CA 15-3 was determined by an automated
enzyme immunoassay based upon two monoclonal antibodies
115-D8 and DF 3 (Enzymun, Boehringer Mannheim; inter-
assay CV: 5%).
Carcinoembryonic antigen
The carcinoembryonic antigen (CEA) was determined by an
automated microparticle enzyme immunoassay (MEIA) based
upon two monoclonal antibodies (IMx, Abbott; inter-assay CV:
10%).
Clinical and physical examination
At each stage (date) of the investigation we compared the results
of the four markers in blood with the results of the clinical
examination, and with the results of medical imaging (if avail-
able), i. e. skeleton scintigraphy, X-ray, or computer tomogra-
phy.
Definition of "bone metastases"
Proof of bone metastases was obtained by skeleton scintigraphy,
X-ray of the bone or computer tomography. In cases of con: ·
tradictory findings the stronger and more precise result was
taken (for instance a positive X-ray is "stronger" than a negative
skeleton scintigraphy, and a positive scintigraphy is "stronger"
than a negative X-ray. Both of these are more significant than
an unsuspicious clinical investigation).
Statist ics
Differences between consecutive investigations
In a first step the differences (absolute and relative) of the four
markers bone alkaline phosphatase, total alkaline phosphatase,
CEA and CA 15-3 between two consecutive times of investi-
' gation were calculated.
The entire evaluation was based on these differences between
two consecutive investigations and not punctual dates of inves-
tigation.
After determining the absolute and relative differences between
the single investigations we calculated mean values, standard
deviations, medians, percentiles, specificity and sensitivity. The




Total alkaline phosphatase was determined according to the
guidelines of the German Society of Clinical Chemistry, on the
Hitachi 717 at 25 °C (inter-assay CV: 5%).
Results
Distribution of differences between two con-
secutive investigations
Figure 1 shows the distribution of the differences of
values for bone alkaline phosphatase. The median of
the differences for group la) is 1 U/l, whereas in group
Ib) (development of bone metastases) it was 10 U/l.
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Fig. l. Distribution of the differences between consecutive values of bone alkaline phosphatase for the 5 groups (from left to
right):
la) unsuspicious follow-up,
Ib) development of bone metastases,
2c) progressive follow-up.
When the second value was outside the reference range the difference is plotted as a dot. When the second value was
inside the reference range (< 70 U/l) the difference is plotted as a triangle.
Group la) (bone metastases but regressive disease)
showed a negative median (—12 U/l) of values cor-
responding to decreasing values from one investiga-
tion to the other. Group 2c) (progressive disease)
revealed a median of 12 U/l (increasing values).
The distribution of the absolute values of the 5 groups
of pairs revealed that group la and 2b, as well as
group Ib and 2c, could be taken together. The lack
of a significant difference between the groups taken
together was confirmed by the Wilcoxon test. Further
calculations were done for the following 2 groups of
investigations:
Group A (n = 97): Continuous follow-up without
bone metastases (la) and stable disease (2b).
Group B (n = 67): Development of bone metastases
at some time during the investigation (Ib) and pro-
gressive disease (2c).
The number of investigations with regressive disease
(2a) was to small to give statistically reliable results.
As expected for group B, the values of all 4 markers
investigated were significantly higher than those for
group A. But also within group A (unsuspicious and
stable follow-up) we observed very large differences
between two consecutive values. These differences
were especially marked for the tumour markers CA
15-3 (363 · 103 U/l) and CEA (54 μ§/1), which is about
15 times the reference range; they were less pro-
nounced for bone alkaline phosphatase (70 U/l) and
alkaline phosphatase (104 U/l, within the reference
range) (tab. 1).
Very similar results were obtained for relative differ-
ences from the preceding values (data not shown in
this publication). However, relative differences have
the drawback of overestimating changes in the range
of low values.
Specificity, sensitivity, positive and negative
predictive value
To investigate the efficiency of a marker in detecting
bone metastases or progressive follow-up, suitable
sensitivities had to be calculated. Thus, sensitivities
were defined as the number of investigations with a
significant increase of the marker compared with the
preceding value, divided by the number of all pairs
investigated in group B (progressive disease). Analo-
gously, specificity was defined by the proportion of
those pairs with clinically unsuspicious follow-up
(group A) that showed no significant increase in value.
A significant increase was defined as a change of value
of more than 2 times the CV (corresponding to a
significant change with a probability of about 70%).
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 12
812 Stieber et al.: Bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases in breast carcinoma
Tab. 1. Differences between consecutive values of bone alkaline phosphatase, alkaline phosphatase, CA 15-3 and CEA for group
A (stable follow-up) and group B (progressive disease and detection of bone metastases).





















































































Tab. 2. Specificity, sensitivity, positive and negative predictive values of CA 15-3, CEA, alkaline phosphatase and bone alkaline




PV + (prevalence 68%) (%)
PV + (prevalence 2%) (%)
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We obtained the highest specificity (70%) for bone
alkaline phosphatase and the lowest (58%) for total
alkaline phosphatase (due to the fact that alkaline
phosphatase consists of several isoenzymes, which
cause many "false positive" results). Conversely, the
bone isoenzyme of alkaline phosphatase revealed the
lowest percentage of true positive results (52%), while
total alkaline phosphatase (67% sensitivity) revealed
the highest percentage (tab. 2).
In addition to specificity and sensitivity, we calculated
the positive and negative predictive values. For this
purpose, the prevalence of progression of metastatic
disease had to be assumed. From our data we assumed
a probability of 68% for progression of disease within
group 2c), so that all 4 markers attained a high
positive predictive value between 77 and 79% (tab. 2).
The probability that the patients without bone me-
tastases (group Ib) would develop involvement of the
bone before the next date of examination was assumed
to be 2%, and the corresponding positive predictive
values varied between 2 and 4%.
Combination of 2 or 3 markers
The aim of the study was to enable a localization of
the metastatic spread by combining the tumour mark-
ers CEA and CA 15-3 with bone alkaline phosphatase.
We therefore restricted the subsequent calculations to
combinations of markers that are relevant to this
question: CEA and CA 15-3 on the one hand, and
bone alkaline phosphatase on the other hand. Both
markers had to fulfil an increase of at least two times
the coefficient of variation. Therefore the number of
false positive results decreases (specificity between 81
and 91%!) and sensitivity is obviously lower (between
27 and 32%) (tab. 3).
In combining the 3 markers, we set the necessary
increase for bone alkaline phosphatase at 2 times the
CV, while at least one of the tumour markers (CEA
or CA 15-3) had to fulfil the same increase.
Under these requirements, specificity decreases a little
to 81%, and the proportion of true positive results
increases to 41%.
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Tab. 3. Specificity, sensitivity, positive and negative predictive values for combinations of bone alkaline phosphatase, alkaline
phosphatase, CA 15-3 and CEA in the detection of bone metastases from breast carcinoma. In each case both markers
have to increase by at least 2 times the coefficient of variation.
Marker Specificity Sensitivity PV + PV -
CEA + Bone alkaline phosphatase
CA 1 5-3 -1- Bone alkaline phosphatase
CEA + Bone alkaline phosphatase
or













Tab. 4. Postulation: 95% specificity of CEA, CA 15-3 and bone alkaline phosphatase and the corresponding required increases
of the sensitivities and the positive and negative predictive values of the markers.
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CA 1 5-3 -f Bone alkaline phosphatase
CEA + Bone alkaline phosphatase
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Claim: Overall specificity of 95%
In order to be able to compare the clinical significance
of the different markers we fixed the specificity for
all single marker determinations and their combina-
tions at 95% (tab. 4).
In order to reach this high fraction of true negative
results the increase of the marker from the first de-
termination to the second had to be very clear — for
example 250% for CEA and 90% for bone alkaline
phosphatase.
Naturally, the sensitivity decreases: 15% for CEA,
and 21% for CA 15-3 and for bone alkaline phos-
phatase. A combination of tumour markers and bone
alkaline phosphatase produces a slight increase of
sensitivity (25% for CA 15-3 and bone alkaline phos-
phatase).
When either CEA or CA 15-3 is combined with bone
alkaline phosphatase the increase of value necessary
to attain a specificity of 95% has to be significantly
lower: 50% for CEA, 18% for CA 15-3 and 30% for
bone alkaline phosphatase. The proportion of true
positive results rises to 37% and the positive predictive
value is 94%.
Thus, when CEA and/or CA 15-3 is combined with
the determination of bone alkaline phosphatase, the
increase of values necessary to demonstrate develop-
ment of metastatic spread to the bone is relatively
low compared with the single determination (tab. 4).
Early detection of bone metastases
Of the 60 patients who started the present investiga-
tion without bone metastases, 30 developed bone in
involvement at some time during the study. Eleven of
these patients were not submitted to any sort of ther-
apy during development of bone metastases. Three
patients showed slightly decreased values of bone
alkaline phosphatase while developing bone metas-
tases, the bone alkaline phosphatase concentration of
one patient was stable, and 7 follow-ups showed in-
creasing values.
This effect becomes clearer when the tumour markers
CEA and CA 15-3 are combined with bone alkaline
phosphatase. Figure 2 demonstrates the parallel and
obvious increase of CEA and bone alkaline phospha-
tase with development of bone metastases.
Discussion
Although metastases are not usually found at the
initial diagnosis of breast carcinoma, local and distant
recurrence of disease is very frequent. Meanwhile it
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Fig. 2. Follow-up of serum CEA, CA 15-3 and bone alkaline phosphatase in a patient with breast carcinoma metastatic to the
bone. (BA. E. $ 73a, operated March 27, 1986 T3 N2 Mx) There is an obvious parallel increase of CEA and bone alkaline
phosphatase with the development of bone metastases.
has been proven by many investigators that blood
markers like CA 15-3 and CEA in breast cancer can
play an important role in the early detection of met-
astatic spread. When determined after primary sur-
gery during the follow-up of breast cancer patients
they often increase and reveal progressive disease long
before it is manifested clinically. But even if tumour
markers indicate a progression of disease, the locali-
zation of metastatic spread represents a great prob-
lem, in view of the low specificity and sensitivity of
bone scanning and X-ray investigations.
From our results it is evident that progression of the
disease is detected very early by the combined deter-
mination, and, moreover, that it is very probably
(depending on the extent of increase) located in bone.
For these reasons, but also from a methodical (the
quantitative determination of bone alkaline phospha-
tase is easy to handle with good reproducibility) and
an economic (determination of bone alkaline phos-
phatase is not expensive but comparable to alkaline
phosphatase) standpoint, the combined determination
of bone alkaline phosphatase, CEA and CA 15-3 for
follow-up investigations of breast cancer patients can
be recommended. We will continue this study in order
to include a greater number of patients, but also to
investigate the role of total alkaline phosphatase, bone
alkaline phosphatase and -glutamyltransferase in the
localization and differential diagnosis of metastatic
spread to the liver and the bone.
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